VANCOUVER, BC / ACCESSWIRE / June 30, 2016 / Alliance Growers Corp. (CSE: ACG) (“Alliance Growers” or the “Company“) is pleased to announce it has signed a Letter of Intent with WFS Pharmagreen Inc. (“Pharmagreen”) where it has previously been agreed that Pharmagreen will provide information about its business and its wholly owned subsidiary, Canna Companion Products Inc. (“Canna”). Alliance Growers proposes to work with and investigate possible joint business interests and opportunities with Pharmagreen and Canna, including a potential full merger of Pharmagreen and Alliance Growers, subject to extensive due diligence and analysis.

Commenting on the acquisition, Dennis Petke, Alliance Growers President and CEO said, “We are absolutely thrilled to have entered into an LOI with Pharmagreen. This presents an opportunity for Alliance Growers to rapidly build out our ‘Four Pillars’ Business Divisions ahead of schedule. This will definitely provide almost immediate value for Alliance Growers shareholders.”

The initial step is a proposal to obtain an exclusive license from Pharmagreen for the marketing, distribution and sales of all present and future Tissue Culture plantlet products utilizing the proprietary “Chibafreen Invitro Plant Production System” for the jurisdiction of Canada, for a fee of CAD$400,000. Consistent quality for mass production for the agriculture and marijuana industry stems from disease-free, genetically identical, healthy starting plant material that can only be truly achieved through Chibafreen Invitro technology.

The execution of the formal license agreement shall be on or before the closing of the Financing referred to below. Additionally both parties agree to possible further development of a “Full Spectrum DNA Botany Lab,” which would be the only such lab facility in Western Canada. A unique blend of clean room lab facilities including a botanical oils extraction lab would be built under the heading of “Botany Center.” Licensing opportunities for the “Botany Center” for the UK and European Union are subject to further negotiations and terms.

Peter Wojcik, CEO of Pharmagreen, stated, “We are very happy to be working with the Alliance Growers’ team. They are a very professional group that will complement our organization and they share our vision of where the industry is going and how to best to capitalize on this vision. When we received the endorsement of Tommy Chong, he said, “The decision to work with Pharmagreen was simple, they are the best at what they do and they care about people and animals. This strategic partnership with Alliance Gowers adds tremendous value to our business going forward.”

Subject to regulatory approval, Alliance Growers will use its best efforts to raise a minimum of CAD$400,000 to a maximum of CAD$500,000 on or before August 31, 2016 by way of a private placement offering of common shares (the “Financing”) to pay the license fee and continue its due diligence in Pharmagreen and its subsidiaries.

About Alliance Growers

Alliance Growers Corp (CSE: ACG) is a diversified cannabis company driven by the Company’s ‘Four Pillars’ Organization Plan – MMPR cannabis production facilities, distribution network, consumer products, and research and development. For further information please visit the Company’s corporate website at www.alliancegrowers.com or the Company’s profile at www.sedar.com.

If you would like to be added to Alliance Grower’s news distribution list, please send your email address to newsletter@alliancegrowers.com

About Pharmagreen

WFS Pharmagreen Inc. is a private company located in Mission, B.C. that is in the business of manufacturing and marketing cannabis-hemp based products for animals and owns the exclusive international rights to all present and future Canna Companion formulations and products. The Company’s executive management team and its advisory committee are composed of a significant mix of professionals that have been carefully gleaned from the fields of private and public company management; veterinary science; human medical science; marketing, branding and business development capped with unparalleled academic and celebrity endorsement. The Company also has a wholly owned subsidiary Canna Companion Products, Inc based in Washington State and operates a 5,000 sq. ft. product production and fulfillment center in Monroe Washington in support of its sales of the Canna Companion products. The Company’s celebrity endorsement is with world renowned Grammy award winning cannabis culture icon, Mr. Tommy Chong, of Cheech & Chong fame, who has never previously been involved with any public company.

On behalf of the board of directors of
ALLIANCE GROWERS CORP.
“Dennis Petke”
Dennis Petke,
CEO

For more information contact:

Dennis Petke
CEO
Tel: 778-331-4266
DennisPetke@alliancegrowers.com

Rob Grace
VP Corporate Development
Tel: 778-998-5431
RobGrace@alliancegrowers.com

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to the use of proceeds of the Financing, as well as the Company’s corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company’s ability to carry out its business plan following the issuance of the required licenses by Health Canada. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company’s ability to identify and complete additional suitable acquisitions to further the Company’s growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

SOURCE: Alliance Growers Corp.

ReleaseID: 441866

NEW YORK, NY / ACCESSWIRE / June 30, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors
that a securities class action has been filed in the United States District, Southern District of New York, on behalf of those who purchased shares of Inovalon Holdings, Inc. (“Inovalon” or the “Company”) (NASDAQ: INOV), pursuant or traceable to the Registration Statement and Prospectus (collectively, the “Registration Statement”) issued in connection with Inovalon’s February 12, 2015 initial public offering (“IPO”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1933.

Inovalon is a technology company based in Bowie, Maryland. It uses cloud-based analytics and technology to help clients achieve insights that approve clinical and quality outcomes, utilization and financial performance in the healthcare industry.

In February, 2015, Inovalon issued over 25 million shares of its common stock for $27 per share, raising over $684 million in gross proceeds.

The complaint alleges that the Registration Statement released in connection with the IPO contained falsified statements and omitted to state material facts required by governing regulations and necessary for investors to make an informed decision. Defendants failed to disclose that Inovalon makes a large percentage of its revenue from sales in the City of New York and the State of New York, both of which were restructuring their corporate tax schemes in order to capture more taxes from out-of-state businesses like Inovalon doing substantial business within their borders. The corporate tax rate increased, effective January 1, 2015, which was more than a month prior to Inovalon’s IPO, significantly inflated Inovalon’s effective tax rate, lowering its 2015 revenue potential. This information should have been included in the Registration Statement but were not. The Registration Statement claimed that Inovalon’s year-over-year “effective income tax rate…remained relatively stable at 39%.”

Once this information was made public, Inovalon stock dropped. At the time of the filing of the complaint, Inovalon shares were trading below $18 per share, or roughly 33% below the IPO price.

No Class has yet been certified in the above action. To discuss this action, or for any questions, please visit the firm’s site: http://www.bgandg.com/#!inov/kk5vc. You can also contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Inovalon, you have until August 23, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 441676

NEW YORK, NY / ACCESSWIRE / June 30, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased Higher One Holdings, Inc. (“Higher One”) (NYSE: ONE) stock prior to June 30, 2016.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Higher One to an affiliate of Blackboard for $5.15 per share. To learn more about the action and your rights, go to: http://zlk.9nl.com/higher-one-holdings or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, California, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 441864

NEW YORK, NY / ACCESSWIRE / June 30, 2016 / Bronstein, Gewirtz & Grossman, LLC, reminds investors of class action against Intrexon Corporation (“Intrexon” or “the Company”) (NYSE: XON). The class action has been filed on behalf of a class consisting of all persons or entities who purchased Horsehead securities between May 12, 2014 and April 20, 2016, both dates inclusive (the “Class Period”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The Complaint alleges that certain officers and directors have issued materially false and misleading statements and/or failed to disclose opposing information to investors. On April 21, 2016, Spotlight Research reported about Intrexon that: (1) Intrexon’s technology is being questioned by the WHO, CDC and NIH; (2) Intrexon exaggerated its revenues by 50% through dealings with related parties; (3) Intrexon’s technology program is just overhyped failed products; and (4) Intrexon is the Theranos of the public markets. Following this news, Intrexon stock dropped $9.73 per share or over 26%, to close at $27.10 per share on April 21, 2016.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint and join the action, visit the firm’s website: http://www.bgandg.com/#!xon/pj7k7. To discuss this action, or have any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Intrexon you have until July 5, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 441567

NEW YORK, NY / ACCESSWIRE / June 30, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States District Court, Southern District of New York on behalf of those who purchased shares of Express Scripts Holding Company (“Express Scripts” or the “Company”) (NASDAQ: ESRX) between February 24, 2015 and March 21, 2016 inclusive (the “Class Period”).

The complaint alleges that throughout the Class Period Express Scripts failed to disclose and/or misled investors regarding its relationship and contract with client Anthem, Inc.

On January 12, 2016, Anthem, Inc. openly threatened to cease its relationship with Express Scripts if Express Scripts would not agree to deliver more than $3 billion in annual savings to Anthem. Following this news, Express Scripts dropped $5.89 per share, or 6.88%, to close at $79.69 on January 13, 2016. Then, on March 21, 2016, Anthem charged Express Scripts, claiming that the Company violated its contract with Anthem by failing to negotiate drug pricing terms in good faith. The opening of this lawsuit exposed a battle between Express Scripts and Anthem going back as early as February 2015, and included accusations that Express Scripts had significant operational problems that interfered with its ability to properly serve Anthem and exposed Anthem to additional monitoring. Shareholders also learned that Anthem would be renegotiating its contract to pay billions of dollars less to Express Scripts, or find a competing pharmacy benefit manager, subsequently losing of Anthem’s business.

No Class has yet been certified in the above action. If you wish to review a copy of the Complaint or join the action, please visit the firm’s site: http://www.bgandg.com/#!esrx/bsz2p. To discuss this action, or for any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Express Scripts you have until July 5, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 441216

NEW YORK, NY / ACCESSWIRE / June 30, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed on behalf of those who purchased shares of Target Corporation (“Target” or the “Company”) (NYSE: TGT) between February 27, 2013 and May 19, 2014 inclusive (the “Class Period”).

The Complaint alleges that throughout the Class Period Defendants issued false and misleading statements to investors and/or failed to
disclose that: (1) when Target opened its first group of stores in Canada it had substantial supply chain infrastructure, distribution centers, and technology systems problems, in addition to poorly trained employees; (2) these problems instigated significant issues, including surplus inventory at distribution centers and insufficient inventory at retail stores; (3) the surplus in inventory at distribution centers and deficiency of inventory at retail locations required Target to severely discount its products and suffer losses; and (4) the supply chain and employee personnel problems were not characteristic of Target’s U.S. based newly launched locations; and (5) as a result, Target’s public statements were materially false and misleading at all relevant times.

No Class has yet been certified in the above action. If you wish to review a copy of the Complaint or join the action, please visit the firm’s site: http://www.bgandg.com/#!tgt/fcdmx. To discuss this action, or for any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Target you have until July 18, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 441134

WOBURN, MA / ACCESSWIRE / June 30, 2016 / SPO Global Inc. (OTC: SPOM) today announced that it has recently successfully installed its new 24/7 performance monitoring software solution “Sentinel” with Nova Scotia, Canada.

Nova Scotia Power Inc. is a vertically integrated electric utility in Nova Scotia, Canada. It is privately owned by Emera and regulated by the provincial government via the Nova Scotia Utility and Review Board. Nova Scotia Power Inc provides electricity to 500,000 residential, commercial and industrial customers in Nova Scotia. For more information: www.nspower.ca.

Commenting on this transaction, Mr. Dukes, CEO S.P.O Global, said, “This is another validation for our recently launched software solution Sentinel, that major enterprises across North America and Canada are beginning to recognize as an essential part of their enterprise applications.”

“We are focusing on our revenue and growth and 2016 is looking to be a great year for our company,” he added.

About SPO Global Inc.

SPO (SOFTWARE PERFORMANCE OPTIMIZATION) GLOBAL INC, is an emerging technology company that is focused on selling its unique performance testing optimization and monitoring software IP for all enterprise applications. The focus of SPO is to build the company into a major player in this exciting billion-dollar market.

SPO Global recently purchased the technology company Reflective Solutions Corp. that sells its unique IP software to major enterprises in North America and Europe.

The principle software products of Reflective Solutions are “Stress Tester,” a robust Performance Stress testing solution for large enterprise applications, and its new product “Sentinel” that is providing enterprise customers an intelligent monitoring solution 24 / 7 software as a service (SaaS).

For more information on SPO Global visit: www.spoglobal.com.

This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry, and that reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to, expectations regarding the successful expansion of our product base, profitability, market acceptance of our products and new product applications, timing of new product launches, product performance, size of prospective markets, marketing strategies, success of our restructured operations and plans, our ability to generate fees or raise capital to support our business operations and plan, the sufficiency and availability of working capital, changes in economic conditions generally and in more specifically, the introduction of competing products, changes in our operating strategy or development plans, patent protection for our products and technologies, changes in economic conditions generally and in more specifically, in the markets we operate, changes in technology, legislative or regulatory changes that affect us. We undertake no obligation to revise or update any forward-looking statement for any reason.

SOURCE: SPO Global Inc.

ReleaseID: 441801

LONDON, UK / ACCESSWIRE / June 30, 2016 / Active Wall St announces its coverage of market signals with highlight on these most active stocks from Wednesday’s session: The Chesapeake Energy Corporation (NYSE: CHK), Marathon Oil Corporation (NYSE: MRO), and Denbury Resources Inc. (NYSE: DNR). Register with us now for your free membership and get more on our signal alerts at:

http://www.activewallst.com/register/

Oil Price Update

Crude Oil prices jumped on Wednesday, June 29, 2016, with Brent crude rising above the psychological $50 a barrel mark, after the U.S. Energy Information Administration reported that domestic crude supplies fell by 4.1 million barrels for the week ended June 24, 2016. Waning concerns over Britain’s exit from the European Union, prospects of oil workers’ strike in Norway and a crisis in Venezuela’s energy sector added to the rise in crude futures.

Today, AWS is promoting its market signals coverage with emphasis on CHK, MRO, and DNR. Get all of our reports for free by signing up to http://www.activewallst.com/register/

Here we take a look at some of the most active share in the Oil & Gas Sector.

Most Active – Chesapeake Energy

On Wednesday, shares in Chesapeake Energy Corp. ended the trading session at $4.42, up 3.27% above its previous day’s closing. Chesapeake Energy’s stock recorded trading volume of 29.66 million shares, lower than its three months average volume of 40.93 million shares. The stock oscillated between an intraday range of $4.33 and $4.50. Chesapeake Energy’s shares are up 7.28% in the last three months. The company’s stock is trading 8.45% and 12.88% below its 50-day and 200- day moving average.

Most Active – Marathon Oil

Shares of Marathon Oil Corporation ended Wednesday’s trading session 2.44% higher at $15.14. A total of 24.14 million shares were traded, which was above its three months average volume of 22.23 million shares. The stock vacillated between $14.84 and $15.45 during the session. Over the last one month and the previous three months, Marathon Oil’s shares have increased 15.84% and 36.46%, respectively. Furthermore, since the beginning of 2016, the company’s stock has advanced 21.61%. The company’s shares are trading 12.72% above its 50-day average and 14.57% above its 20-day moving average.

Most Active – Denbury Resources

On Wednesday, shares in Denbury Resources Inc. recorded a trading volume of 15.73 million shares, which was above its three months average volume of 13.79 million shares. The stock ended the day at $3.80, which was 1.55% lower than its previous closing price. The stock registered an intraday range of $3.79 and $4.06. Denbury Resources’ shares have gained 71.17% and 88.12, in the previous three months and YTD, respectively. Denbury Resources’ stock is trading 53.52 times its forward P/E ratio and is 31.58% above its 200-day moving averages Furthermore, shares of the company have an RSI of 43.29.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated directly or indirectly for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 441857